Champions Oncology (CSBR) Other Non-Current Assets (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Other Non-Current Assets of $212000.0 for Q2 2026, up 8.16% year-over-year from $196000.0 in Q2 2025, and up 8.16% quarter-over-quarter from $196000.0 in Q1 2026.
Champions Oncology (CSBR) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Champions Oncology's Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $212000.0 for Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 8.16% year-over-year to $212000.0; the TTM figure through Apr 2026 stood at $212000.0 (up 8.16% YoY), while the FY2026 annual figure was $212000.0, up 8.16% from the prior year.
- Other Non-Current Assets for Q2 2026 stood at $212000.0, up from $196000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $212000.0 in Q2 2026, with the low at $15000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $185000.0 (2023), against an average of $132222.2.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets tumbled 82.56% in 2022, then soared 1133.33% in 2023.
- Champions Oncology's Other Non-Current Assets stood at $15000.0 in 2022, then jumped by 1133.33% to $185000.0 in 2023, then changed by 0.0% to $185000.0 in 2024, then increased by 5.95% to $196000.0 in 2025, then advanced by 8.16% to $212000.0 in 2026.
- Business Quant data shows CSBR's Other Non-Current Assets at $212000.0 in Q2 2026, $196000.0 in Q1 2026, and $196000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | 212,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 212,000.00 |
| Jan 31, 2026 | 196,000.00 |
| Oct 31, 2025 | 196,000.00 |
| Jul 31, 2025 | 196,000.00 |
| Apr 30, 2025 | 196,000.00 |
| Jan 31, 2025 | 185,000.00 |
| Oct 31, 2024 | 185,000.00 |
| Jul 31, 2024 | 185,000.00 |
| Apr 30, 2024 | 185,000.00 |
| Jan 31, 2024 | 185,000.00 |
| Oct 31, 2023 | 185,000.00 |
| Jul 31, 2023 | 184,000.00 |
| Apr 30, 2023 | 15,000.00 |
| Jan 31, 2023 | 15,000.00 |
| Oct 31, 2022 | 15,000.00 |
| Jul 31, 2022 | 15,000.00 |
| Apr 30, 2022 | 15,000.00 |
| Jan 31, 2022 | 15,000.00 |
| Oct 31, 2021 | 15,000.00 |
| Jul 31, 2021 | 86,000.00 |